E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Continued research toward the development of new antifungals that act via inhibition of glycosylphosphatidylinositol (GPI) biosynthesis led to the design of E1210. In this study, we assessed the selectivity of the inhibitory activity of E1210 against Candida albicans GWT1 (Orf19.6884) protein, Aspergillus fumigatus GWT1 (AFUA_1G14870) protein, and human PIG-W protein, which can catalyze the inositol acylation of GPI early in the GPI biosynthesis pathway, and then we assessed the effects of E1210 on key C. albicans virulence factors. E1210 inhibited the inositol acylation activity of C. albicans Gwt1p and A. fumigatus Gwt1p with 50% inhibitory concentrations (IC 50 s) of 0.3 to 0.6 μM but had no inhibitory activity against human Pig-Wp even at concentrations as high as 100 μM. To confirm the inhibition of fungal GPI biosynthesis, expression of ALS1 protein, a GPI-anchored protein, on the surfaces of C. albicans cells treated with E1210 was studied and shown to be significantly lower than that on untreated cells. However, the ALS1 protein levels in the crude extract and the RHO1 protein levels on the cell surface were found to be almost the same. Furthermore, E1210 inhibited germ tube formation, adherence to polystyrene surfaces, and biofilm formation of C. albicans at concentrations above its MIC. These results suggested that E1210 selectively inhibited inositol acylation of fungus-specific GPI which would be catalyzed by Gwt1p, leading to the inhibition of GPI-anchored protein maturation, and also that E1210 suppressed the expression of some important virulence factors of C. albicans , through its GPI biosynthesis inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prodrug is metabolized by phosphatases and converted to manogepix (APX001A, formerly E1210) which inhibits the Gwt1 but not the human homolog Pig-W (Watanabe et al., 2012; Wiederhold et al., 2019).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Watanabe et al., 2012
In the citing paper
“MGX inhibits the conserved fungal glycosylphosphatidylinositol (GPI)-anchored wall transfer protein 1 (Gwt1) (13, 14).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [14]
In the citing paper
“There is limited information on the activity of this new class of antifungals, but in an early study manogepix inhibited C. albicans adherence and biofilm formation in a concentration dependent manner among other virulence factors [47].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [47]
In the citing paper
“E1210 is a broad-spectrum antifungal agent with a novel mechanism of action based on the inhibition of fungal glycosylphosphatidylinositol biosynthesis [144, 145].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [144]
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801 · cited 1×
“The incidence of life-threatening fungal infections has increased steadily over the past 2 decades as a result of an increase in the number of susceptible immunosuppressed patients (39, 68).”
BackgroundLee, K. L., Buckley, H. R., & Campbell, C. C. (1975) · Medical Mycology · doi:10.1080/00362177585190271 · Cited by 788 · cited 1×
“5% glucose (YNB), Spider medium (31), Lee’s medium (28), YPD broth (Becton Dickinson Company) supplemented with 10% fetal calf serum (FCS), and yeast nitrogen base without amino acids but supplemented with 2.”
MethodSuppression of Hyphal Formation in Candida albicans by Mutation of a STE12 Homolog
Liu, H., Köhler, J., & Fink, G. R. (1994) · Science · doi:10.1126/science.7992058 · Cited by 786 · cited 1×
“5% glucose (YNB), Spider medium (31), Lee’s medium (28), YPD broth (Becton Dickinson Company) supplemented with 10% fetal calf serum (FCS), and yeast nitrogen base without amino acids but supplemented with 2.”
MethodStandardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“Resistance is also becoming an increasing problem, particularly among members of the azole class (33, 44, 45, 47, 66).”
BackgroundRamage, G., Saville, S. P., Thomas, D. P., & López-Ribot, J. L. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.4.633-638.2005 · Cited by 678 · cited 2×
“albicans have each been reported to be associated with biofilm formation (3, 41, 49).”
BackgroundMethodArchitecture of the Yeast Cell Wall
Kollár, R., Reinhold, B. B., Petráková, E., Yeh, H. J. C., Ashwell, G., Drgonová, J., Kapteyn, J. C., Klis, F. M., & Cabib, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17762 · Cited by 644 · cited 1×
“synthesis and assembly are GPI anchored, and GPI synthesis and/or anchoring is essential for cell viability in yeasts (27, 29, 43, 46).”
BackgroundThe ALS gene family of Candida albicans.
Hoyer, L. L. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)01984-9 · Cited by 540 · cited 1×
“Examples of GPI-anchored virulence factors are the Als protein family, adhesins with broad substrate specificity (15, 23, 55); Hwp1p, an epithelial adhesin and biofilm promoter (40); Eap1p, an adhesin to epithelial cells and polystyrene surfaces (30); secreted aspartyl proteinases Sap9p and Sap10p, phospholipase B Plb…”
Background
Research works printed but not linked: 3
- Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-third edition M27–A3. Clinical and Laboratory Standards Institute Wayne PA.
- SmithTK. 2009. Inhibitors of GPI biosynthesis, P. 247–267. In MenonAK KinoshitaT OrleanP TamanoiF (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins, Academic Press, London, United Kingdom.
- Yoko-oT JigamiY. 2009. Inositol acylation/deacylation, p. 65–90. In MenonAK KinoshitaT OrleanP TamanoiF (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins. Academic Press, London, United Kingdom.
Cited by
Items 101–175 of 175
Hatamoto, M., Aizawa, R., Koda, K., & Fukuchi, T. (2021) · Journal of Pesticide Science · doi:10.1584/jpestics.d20-094 · Cited by 23
Novel avenues for identification of new antifungal drugs and current challenges
Jampílek, J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2097659 · Cited by 21
“The molecule has a broad therapeutic index [88].”
BackgroundLee, A., Wang, N., Carter, C. L., Zimmerman, M., Dartois, V. A., Shaw, K. J., Perlin, D. S., & Zhao, Y. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-20 · Cited by 21
“MGX inhibits the conserved fungal enzyme inositol acyltransferase Gwt1 in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway, thereby disrupting the trafficking and anchoring of mannoproteins to the fungal cell wall (13, 14).”
BackgroundCytotoxic and Antifungal Amides Derived from Ferulic Acid: Molecular Docking and Mechanism of Action
de Morais, M. C., Pérez‐Castillo, Y., Silva, V. R., Santos, L. D. S., Soares, M. B. P., Bezerra, D. P., de Castro, R. D., & de Sousa, D. P. (2021) · BioMed Research International · doi:10.1155/2021/3598000 · Cited by 21
Cruz, R., & Wuest, W. M. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133268 · Cited by 19
Espinel‐Ingroff, A., & Wiederhold, N. P. (2024) · Journal of Fungi · doi:10.3390/jof10050362 · Cited by 19
“This agent has broad-spectrum activity against many pathogenic yeast, molds, and dimorphic fungi (e.g., Coccidioides spp.), including C. auris and azole-resistant Aspergillus fumigatus [6,13].”
BackgroundAzole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris
Toepfer, S., Keniya, M. V., Lackner, M., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10100698 · Cited by 23
Liu, W., Zou, Z., Huang, X., Shen, H., He, L. J., Chen, S. M., Li, L. P., Yan, L., Zhang, S. Q., Zhang, J. D., et al. (2016) · Scientific Reports · doi:10.1038/srep34854 · Cited by 20
Combatting Fungal Infections: Advances in Antifungal Polymeric Nanomaterials
Schaefer, S., Corrigan, N. A., Brunke, S., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00866 · Cited by 20
All about that fat: Lipid modification of proteins in Cryptococcus neoformans
Santiago-Tirado, F. H., & Doering, T. L. (2016) · The Journal of Microbiology · doi:10.1007/s12275-016-5626-6 · Cited by 17
“This may explain why inhibitors of S. cerevisiae Gwt1 are active against a broad range of yeasts and molds, but not against C. neoformans (McLellan et al., 2012; Watanabe et al., 2012).”
A New Small-Molecule KRE2 Inhibitor Against Invasive Candida Parapsilosis Infection
Salci, T. P., Negri, M., Abadio, A. K. R., Mendonca, P., Capoci, I. R. G., Caparroz‐Assef, S. M., Donatti, L., Felipe, M. S. S., Kioshima, É. S., & Svidzinski, T. I. E. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0065 · Cited by 17
Pharmacokinetics–pharmacodynamics of antifungal agents in the central nervous system
Stott, K. E., & Hope, W. W. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1492551 · Cited by 17
cspAInfluences Biofilm Formation and Drug Resistance in Pathogenic FungusAspergillus fumigatus
Fan, Z., Li, Z., Xu, Z.-G., Li, H., Li, L., Ning, C., Ma, L., Xie, X.-L., Wang, G., & Yu, H. (2015) · BioMed Research International · doi:10.1155/2015/960357 · Cited by 19
“Under natural conditions, such as in human bodies, most fungal and bacterial pathogens are present as part of a biofilm, which contributes to their decreased response to antibiotics and host immune defenses compared with bacteria in the planktonic state [4].”
BackgroundCurrent Challenges and Updates on the Therapy of Fungal Infections
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/156802661907190531093808 · Cited by 18
Wiederhold, N. P., & Patterson, T. F. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000203 · Cited by 23
“E1210 has potent in-vitro activity against different pathogenic fungi, including Candida, Aspergillus, Fusarium, and Scedosporium species [72–76], and appears to be fungal specific as it does not inhibit human inositol acylation [77].”
BackgroundQureshi, Z. A., Ghazanfar, H., Altaf, F., Ghazanfar, A., Hasan, K. Z., Kandhi, S., Fortuzi, K., Dileep, A., & Shrivastava, S. (2024) · Cureus · doi:10.7759/cureus.55498 · Cited by 20
“Thus, the drug affects the maturation and localization of glycosylphosphatidylinositol (GPI)-anchored mannoproteins by inhibiting the inositol acetylation of fungal GPI proteins [69,70].”
BackgroundInfluentialHirayama, T., Miyazaki, T., Tanaka, R., Kitahori, N., Yoshida, M., Takeda, K., Ide, S., Iwanaga, N., Tashiro, M., Takazono, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01508-24 · Cited by 15
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis
Giamberardino, C. D., Schell, W. A., Tenor, J. L., Toffaletti, D. L., Palmucci, J. R., Marius, C., Boua, J.-V. K., Soltow, Q. A., Mansbach, R. S., Moseley, M. A., et al. (2022) · mBio · doi:10.1128/mbio.02347-22 · Cited by 15
“itory concentration (IC50) for inhibition of the Candida albicans and Aspergillus fumigatus Gwt1 proteins (7).”
BackgroundMethodInfluentialNovel Strategies Against Candida Biofilms: Interest of Synthetic Compounds
Girardot, M., & Imbert, C. (2015) · Future Microbiology · doi:10.2217/fmb.15.118 · Cited by 16
Aspergillus fumigatusCap59-like protein A is involved in α1,3-mannosylation of GPI-anchors
Krüger, A., Engel, J., Buettner, F. F. R., & Routier, F. H. (2015) · Glycobiology · doi:10.1093/glycob/cwv078 · Cited by 16
“This compound inhibits proliferation of several medically relevant fungi including A. fumigatus and improves survival of infected mice (Hata et al. 2011; Pfaller et al. 2011; Watanabe et al. 2012).”
BackgroundGebremariam, T., Alkhazraji, S., Gu, Y., Singh, S., Alqarihi, A., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01966-19 · Cited by 14
“Gwt1 catalyzes an early step in glycosylphosphatidylinositol (GPI) anchor biosynthesis (3, 4), and inhibition of this enzyme has pleiotropic effects on cell wall integrity, biofilm formation, and fungal growth (5, 6).”
BackgroundHodges, M. R., Hazel, S., Kramer, W. G., van Hoogdalem, E., van Marle, S., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01455-23 · Cited by 13
Combination therapy for the treatment of pulmonary mold infections
McCarthy, M. W., Petraitis, V., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1325322 · Cited by 15
How do I manage refractory invasive pulmonary aspergillosis
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12
Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens
Liston, S. D., Whitesell, L., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2022) · Journal of Fungi · doi:10.3390/jof8101102 · Cited by 12
“Genetic findings indicate that complete loss of GWT1 function is fungicidal, while partial blockade of the pathway by inhibitors is fungistatic [19,20].”
BackgroundNickels, T. J., Gale, A. N., Harrington, A. A., Timp, W., & Cunningham, K. W. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae173 · Cited by 12
Synthesis and Biological Evaluation of Novel 2‐Aminonicotinamide Derivatives as Antifungal Agents
Ni, T., Li, R., Xie, F., Zhao, J., Huang, X., An, M., Zang, C., Cai, Z. J., Zhang, D., & Jiang, Y. (2017) · ChemMedChem · doi:10.1002/cmdc.201600545 · Cited by 12
Jha, A., & Kumar, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0479 · Cited by 12
Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis
McCarthy, M. W., Aguilar-Zapata, D., Petraitis, V., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1283986 · Cited by 11
“E1210/APX001 inhibits a step in the glycosylphosphatidylinositol (GPI)-dependent anchoring of mannosylated cell wall proteins attached to the polysaccharide wall component [132].”
BackgroundMcCarthy, M. W., & Walsh, T. J. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1488589 · Cited by 12
Li, D. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-58843-3_16 · Cited by 11
Liston, S. D., Whitesell, L. J., McLellan, C. A., Mazitschek, R., Petraitis, V., Petraitienė, R., Kavaliauskas, P., Walsh, T. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00899-20 · Cited by 13
“Neither manogepix nor gepinacin inhibits the orthologous mammalian acyltransferase PIG-W, and both have broad-spectrum activity against diverse fungal pathogens (12, 15).”
BackgroundTherapeutic Approaches for Combating Aspergillus Associated Infection
Chhillar, A. K., Punia, A., Choudhary, P., Sharma, N., Dahiya, S., & Gulia, P. (2022) · Current Drug Targets · doi:10.2174/1389450123666220623164548 · Cited by 10
Konings, M., Eadie, K., Strepis, N., Nyuykonge, B., Fahal, A. H., Verbon, A., & van de Sande, W. W. J. (2023) · Medical Mycology · doi:10.1093/mmy/myad118 · Cited by 9
“15 Studies have shown that manogepix is active against different clinically relevant moulds, including azole-and echinocandin-resistant Aspergillus spp. and Candida spp. 14 , 16 , 17 Given the potential of manogepix, the aim of our study was threefold.”
BackgroundHata, K. (2020) · Parasitology International · doi:10.1016/j.parint.2020.102278 · Cited by 10
Self-citationEumycetoma: pathogenesis, current treatments, and the search for new drugs
Yachioui, D. E., Baltussen, T., & van de Sande, W. W. J. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13580-5 · Cited by 8
“Manogepix Manogepix inhibits GWT1, an enzyme in the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway, resulting in the disruption of mannoproteins formation, which are critical for the fungal cell wall (Watanabe et al. 2012).”
Lipids of Yeasts and Filamentous Fungi and Their Importance to Biotechnology
Passoth, V., & Müller, B. (2025) · Grand challenges in biology and biotechnology · doi:10.1007/978-3-031-74726-7_7 · Cited by 12
Vahedi‐Shahandashti, R., Houbraken, J. A. M. P., Birch, M., & Lass‐Flörl, C. (2023) · Journal of Fungi · doi:10.3390/jof9060649 · Cited by 8
“This leads to defects in various steps of cell wall biosynthesis with the accompanying inhibition of cell wall growth, hyphal elongation, and the attachment of fungal cells to biological substrates [20].”
BackgroundBarbosa, P. D. P. M., Speranza, P., Ohara, A., da Silva, É. B., Attili‐Angelis, D., & Macêdo, G. A. (2017) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2017.01.011 · Cited by 8
Inhibition of morphological transition and hyphae extension in Candida spp. by occidiofungin
Kumpakha, R., & Gordon, D. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15425 · Cited by 7
“The fungicidal agent amphotericin B and the echinocandins, mulundocandin and micafungin, are reported to be effective at blocking morphogenetic transformation (Hawser & Islam, 1999; Watanabe et al., 2012).”
BackgroundNew Perspectives on Antimicrobial Agents: Fosmanogepix
Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 6
“Manogepix (MGX, formerly referred to as E1210 or APX001A), the active moiety of FMGX (APX001), targets Gwt1, an enzyme localized in the endoplasmic reticulum and involved in the biosynthesis pathway of glycosylphosphatidylinositol (GPI)-anchored mannopro teins (transfer of an acyl group) (17, 18).”
Infection caused by Candida auris: state of the art
Marena, G. D., Carvalho, G. C., Monazzi, L., Maschio-Lima, T., Almeida, M. D., Silva, J. D., Fortunato, G., Araújo, V., Venancio, D. C. V., Chang, M., et al. (2022) · Mycosphere · doi:10.5943/mycosphere/13/1/10 · Cited by 6
Zhai, H., Zeng, J., Ma, X., Wang, F., Xu, W., Song, M., & Xu, W. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1562103 · Cited by 6
Milsap, D., Okuno, M., Kigozi, E., Mugabi, T., Ssekindi, F., Bajer, A., Gakuru, J., & Bahr, N. C. (2025) · Microorganisms · doi:10.3390/microorganisms13040847 · Cited by 5
“Fosmanogepix and APX2039 target the fungal enzyme Gwt1, disrupting glycosylphosphatidylinositol anchor synthesis, thereby affecting fungal growth [46].”
Drug Discovery and Repurposing for Coccidioides: A Systematic Review
Saeger, S., Lozano, S., Wiederhold, N. P., Yu, J., Lopez-Ribot, J. L., & Hung, C.-Y. (2025) · Journal of Fungi · doi:10.3390/jof11120875 · Cited by 5
“It mainly impacts the biosynthesis of GPI-anchored mannoproteins, which compromise the integrity of the cell wall, disrupting fungal growth and adherence [100–102].”
Inhibitory effect of copper chelators on the budding in Candida albicans
Futamura, Y., Yamamoto, K., Uson‐Lopez, R. A., Aono, H., Shimizu, T., Hori, Y., Kino, K., & Osada, H. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00033-25 · Cited by 4
“Therefore, dimorphism modulators have been examined by many researchers to develop antifungal drugs with new mechanisms of action (11–13).”
InfluentialNew Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 6
Kinniment-Williams, B. E., Jurgeleviciute, V., West, D., Herman, R., Blaza, J. N., van der Woude, M. W., & Thomas, G. H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110546 · Cited by 4
“In fungi the same protein, called GWT1, is required for the synthesis of their complex cell envelope and has been targeted in the development of novel anti-fungal (38) and anti-parasitic drugs (39).”
Oak, A. S. W., Baddley, J. W., & Elewski, B. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-66884-0_40 · Cited by 6
Seyedmousavi, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc295 · Cited by 4
Garnham, M. D., Agüero, F., Ramírez, J. C., Agüero, F., & Salas‐Sarduy, E. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00900 · Cited by 3
The top three areas of basic research on Aspergillus fumigatus in 2011
Osherov, N. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06798.x · Cited by 3
Search for new antimycotic agents: main trends and problems
Новикова, В. В. (2020) · Человек и его здоровье · doi:10.21626/vestnik/2020-1/09 · Cited by 3
Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients
Cabrera, N. L., George, I. A., Rauseo, A. M., Mazi, P. B., & Spec, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000995 · Cited by 3
Coenzyme A metabolism in fungi: a new frontier in antifungal therapy
Choi, J., Chiang, A., & Mamoun, C. B. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00307-25 · Cited by 1
“Fosmanogepix (APX001), a first-in-class Gwt1 enzyme inhibitor, targets the glycosylphos phatidylinositol (GPI) anchor biosynthesis pathway, which is essential for fungal cell wall integrity and virulence (69, 70).”
Hsieh, M., Choi, P., Wu, W.-L., Lin, Y.-F., & Wu, C. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02659-25 · Cited by 1
“Manoge pix inhibits the fungal enzyme Gwt1, blocking GPI anchor biosynthesis, disrupting cell wall protein anchoring, and thereby compromising cell wall integrity and viability (48).”
Weeks, S., Brown, A., Doughty, K., Armstrong-James, D. P. H., Bennett, N., Birch, M., Borman, A. M., Bromley, M., Bryson, R., Fisher, M. C., et al. (2026) · npj Antimicrobials and Resistance · doi:10.1038/s44259-026-00220-9 · Cited by 1
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1
de Medeiros, M. A. P. (2013) · Americanae (AECID Library)
Molecular Targets for Anticandidal Chemotherapy
Milewski, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_21
(2016) · Elsevier eBooks · doi:10.1016/b978-0-12-811311-0.00016-8
Novel Therapeutic Approaches to Control Fungal Biofilms
Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11
de Cesare, M. A., Lopes, M. S., Vainstein, M., & de Andrade, S. D. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146139
Wang, Y. (2023) · MacSphere (McMaster University) · doi:10.71548/17335 · Cited by 1
Modern trends in the development of antifungal agents
Avtonomova, A. V., Валерьевна, К. О., Zagainova, A. V., & Makarov, V. V. (2025) · Экология человека · doi:10.17816/humeco695458
Avtonomova, A. V., Валерьевна, К. О., Lysenkova, L. N., & Krasnopolskaya, T. S. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-9-10-62-76
Galland, E. (2013) · theses.fr (ABES) · doi:10.70675/cea4cde4z7649z41a5z8597z63e86dea636a · Cited by 1
Hameed, T., John, L. L. H., Bignell, E., & Tanaka, R. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733372
“In general, MGX is known to inhibit the Gwt1 enzyme, which is crucial for fungal cell wall integrity [27], causing growth defects, such as loss of the ability to form biofilms [27] or filament [28].”
Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Zhu, G., Zheng, N., Zhai, P., & Mou, Y. (2026) · Biomedical Reports · doi:10.3892/br.2026.2204
“Systematic structure‑activity relation‑ ship studies based on BIQ optimized their pharmacological properties while preserving antifungal activity, ultimately leading to the preclinical candidate E1210 (manogepix) (28).”
Dharmapalan, D., Singh, M., El-Shabrawi, M. H. F., Murray, T. S., Sadoh, A. E., Simental, L. P. S., Ibanes-Gutiérrez, C., Efstathiou, E., Fathy, H. M., Rath, B. A., et al. (2026) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2026.1970689
Alaithan, H., & Granillo, A. (2026) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361261499196
BindingDB (2022) · UC San Diego · doi:10.7270/q2348q30
Baillod, A., Clarhaut, J. A., Keomany, L., Moreau, J., Marchand, S., & Brunet, K. (2026) · Virulence · doi:10.1080/21505594.2026.2753345
Metadata
- Authors
- Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K.
- Affiliations
- Next Generation Systems Core Function Unit, Eisai Product Creation Systems, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
- Eisai (Japan) (JP)
- ORCID
- Sagane, Koji
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-02
- Volume
- 56
- Issue
- 2
- Pages
- 960-971
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3264227
- OpenAlex
- W1987354838
- Cited by
- 169
- References
- 67
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 20 · 2023: 14 · 2022: 14 · 2021: 11 · 2020: 14 · 2019: 15 · 2018: 12 · 2017: 14 · 2016: 6 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 2
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, Candida albicans, Aspergillus fumigatus, glycosylphosphatidylinositol biosynthesis, virulence factors, germ tube formation, biofilm formation, ALS1, Rho1
- MeSH terms
- Acylation, Aminopyridines, Antifungal Agents, Candida albicans, Candidiasis, Fungal Proteins, Humans, Inositol, Isoxazoles, Virulence, Gene Expression Regulation, Fungal, Glycosylphosphatidylinositols, Hyphae, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.